Düsseldorf, January 3, 2022 – Alexander Rieg took over the position of Daniel Seidl as Managing Director at iuvo Therapeutics GmbH at the turn of the year.
With effect from January 1, 2022, Alexander Rieg is officially the new Managing Director of iuvo. The pharmaceutical company based in Düsseldorf and Potsdam has a focus on cannabinoid-based drugs. As Managing Director, Mr. Rieg will be responsible for controlling the company and will continue to develop it successfully. In his previous position on the iuvo management team, he made a significant contribution to the company’s business development. Most recently, he worked as an independent consultant in the medical cannabis industry. That was after he founded GECA Pharma GmbH in 2017. He also was a founding member of the Federal Association of Pharmaceutical Cannabinoid Companies. V. (BPC).
“I am very pleased that we were able to find such an experienced Managing Director in Alexander Rieg. He has not only helped to shape the medical cannabis industry since day one, but also has a deep understanding of the German healthcare system,” explains Daniel Seidl, co-founder of iuvo Therapeutics. Seidl will continue to support the company strategically as COO. He has been Managing Director of iuvo Therapeutics GmbH since it was founded in 2017.
“I would like to express my sincere gratitude for the valuable work that Mr. Seidl has done and the trust that the shareholders have placed in me. With his work, Mr. Seidl laid the cornerstone for iuvo’s success. On this foundation, I will position the company for the future,” says Alexander Rieg.
About iuvo Therapeutics
iuvo Therapeutics is a pharmaceutical company founded in 2017 and headquartered in Düsseldorf. iuvo’s goal is the reliable supply of high-quality cannabis-based medicines to patients within Europe. iuvo is an independent importer, manufacturer, and wholesaler, constantly expanding its supply chain focusing on established GMP- and GDP-compliant partners. The distribution of our products takes places directly to pharmacies as well as through selected pharmaceutical wholesalers.
iuvo develops its pharmaceuticals based on the latest scientific knowledge. In cooperation with experts in cannabis therapy, the company supports doctors and pharmaceutical specialists through recognized scientific training courses.
iuvo Therapeutics is also an active member of the Federal Association of Pharmaceutical Cannabinoid Companies.
For all media enquiries:
Tibor Rietzsch Junge, M.Eng.
Head of Marketing & PR
Tel. +49 (0) 17674738014
Email: t.rietzsch.j@iuvo-therapeutics.com
www.iuvo-therapeutics.com
